Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EHA 2016: Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Paul Richardson (Harvard Medical School, Boston, USA) and Professor Maria-Victoria Mateos (Salamanca, Spain) discuss the meta-analysis of OS in myeloma with maintenance therapy presented at ASCO and EHA this year, along with strategies for continuous therapies

Written by | 3 Aug 2016

Consolidation and maintenance therapy for multiple myeloma: is it the new standard?   Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Written by | 19 Jul 2016

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

EHA 2016: How monoclonal antibodies will change the treatment of multiple myeloma. Professor Antonio Palumbo (Torino, Italy) discuss the results of the CASTOR trial and Professor Meletios-Athanasios Dimopoulos (Athens, Greece) discussing POLLUX.

Written by | 15 Jul 2016

How monoclonal antibodies will change the treatment of multiple myeloma  by Maria Dalby   Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.

ASCO 2016: Elderly glioblastoma patients achieve longer survival with radiation plus temozolomide

Written by | 5 Jul 2016

by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.

ASCO 2016: Previously untreatable advanced bladder cancer patients respond to immunotherapy

Written by | 4 Jul 2016

by Bruce Sylvester: Anti-PD-L1 immunotherapy atezolizumab (TECENTRIQ) has shown efficacy in previously untreated patients with advanced bladder cancer who are ineligible for standard treatment with cisplatin.

ASCO 2016: Targeted therapy shows efficacy in advanced small cell lung cancer

Written by | 1 Jul 2016

by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.

ASCO 2016: Melanoma 3-year survival is robust after pembrolizumab treatment

Written by | 30 Jun 2016

by Bruce Sylvester: A follow-up evaluation of subjects from the phase 1b trial (KEYNOTE-001) of newly diagnosed and previously treated patients with advanced melanoma revealed a 40% survival… read more.

ISH/BSH 2016: Changing treatment paradigms in multiple relapse HL

Written by | 8 Jun 2016

Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.

ISH/BSH 2016: Professor John Radford (The University of Manchester) and Dr Graham Collins (Oxford University Hospitals) discuss the key issues to come out of the session on challenging current clinical practices in HL. Also included associated article entitled 'Rethinking risk for better outcomes in ASCT'

Written by | 7 Jun 2016

Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.

ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

Written by | 2 Jun 2016

High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Written by | 2 Jun 2016

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

World Health Matters: Italy – 3D screening detects more cancers in dense breast tissue

Written by | 25 May 2016

by Gary Finnegan: Researchers have found that in over 3,000 Italian women with dense breasts where standard mammograms had not detected any cancer, the addition of tomosynthesis (a… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.